Avalo Therapeutics, Inc. (AVTX)
22.48
+0.67
(+3.07%)
USD |
NASDAQ |
May 07, 14:41
Avalo Therapeutics SG&A Expense (TTM) : 22.90M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Catalyst Pharmaceuticals, Inc. | 171.18M |
| AbbVie, Inc. | 14.30B |
| Relmada Therapeutics, Inc. | 32.22M |
| Theravance Biopharma, Inc. | 78.40M |
| Corcept Therapeutics, Inc. | 503.42M |